Japan Generics Mandate Leads To Reduction In Maker Portfolios
This article was originally published in PharmAsia News
Executive SummaryJapan's three-year-old policy regarding generic drugs is beginning to lead pharmaceutical companies to focus their marketing efforts on top sellers
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.